Overview

NG101 is our lead clinical program for wet AMD, designed to address the heavy treatment burden of frequent standard-of-care injections. Utilizing an AAV8 vector, it delivers a codon optimized aflibercept gene via a single subretinal administration for durable, long-term disease control. The FDA has granted Fast Track designation for NG101. 

EG103 is a first-in-class investigational AAV gene therapy for geographic atrophy associated with dry AMD. It is designed as a single administration to drive sustained intraocular expression of TAFA4, a secreted neuro-supportive protein intended to help maintain retinal synaptic structure and signaling. By targeting retinal synaptic dysfunction as a key contributor to functional decline in GA, EG103 aims to support durable preservation of visual function from a one-time treatment. 

EG201 is a first in class investigational AAV gene therapy for chronic neuropathic pain designed around a disease modifying hypothesis at the dorsal root ganglion neuron and satellite glial cell interface. It is designed as a single dose administration to drive sustained in vivo expression of an scFv targeting FAM19A5, a secreted factor hypothesized to regulate neuron glia association in the dorsal root ganglion. By targeting this mechanism as a contributor to pain persistence, EG201 aims to provide consistent and durable control from a one-time treatment.